# C1QA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The C1QA gene encodes the A-chain of complement component C1q, a crucial pattern-recognition molecule initiating the classical complement pathway, essential for immune complex clearance and apoptotic cell removal.
- Homozygous loss-of-function mutations in C1QA are the strongest monogenic risk factor for Systemic Lupus Erythematosus (SLE), with over 90% of affected individuals developing the disease due to impaired clearance of self-antigens.
- Beyond complement, C1qA participates in non-canonical functions including synaptic pruning in the central nervous system, modulation of Wnt signaling, and enhancement of RIG-I-mediated antiviral responses.
- Pathogenic variants in C1QA, such as missense mutations disrupting the globular C1q domain or collagen triple-helix, lead to complete C1q deficiency and are diagnosed via genetic sequencing.
- C1QA expression is dysregulated in various pathologies, including neurodegenerative diseases (Alzheimer's), psychiatric disorders (schizophrenia), and cancer, where it can serve as a prognostic biomarker influencing treatment strategies.
- Therapeutic strategies for C1q deficiency are primarily supportive, including fresh frozen plasma infusions and hematopoietic stem cell transplantation, while investigational approaches include anti-C1q monoclonal antibodies and siRNA-based therapies.

---

## Executive Summary & Key Metadata

The **C1QA** gene encodes the A-chain polypeptide of complement component C1q, the recognition subcomponent of the C1 complex that initiates the classical complement pathway. C1q is a hexameric or heterotrimeric assembly of 18 polypeptide chains (6 A-chains, 6 B-chains, 6 C-chains) that serves as a pattern-recognition molecule for immune complexes, apoptotic cell surfaces, and pathogen-associated molecular patterns. The C1QA gene product is indispensable for the structural integrity of the C1q molecule; homozygous loss-of-function mutations in C1QA result in complete C1q deficiency, which is the strongest known monogenic risk factor for systemic lupus erythematosus (SLE). Beyond its canonical role in complement activation, C1qA participates in synaptic pruning in the central nervous system, tumor microenvironment remodeling, and modulation of inflammatory signaling cascades. This reference manual provides an exhaustive analysis of the genomic architecture, structural biology, signaling networks, pathogenic mutations, and clinical relevance of C1QA.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | C1QA |
| **UniProt Accession** | P02745 |
| **Representative PDB ID** | 1PK6 (C1qA–C1qC heterotrimer globular domain) |
| **Chromosomal Locus** | 1p36.12 (GRCh38: chr1:22,636,863–22,639,645, minus strand) |
| **Primary Molecular Function** | Pattern recognition; classical complement pathway initiation; C1q complex assembly |
| **Disease & Pathology Associations** | Systemic lupus erythematosus (SLE), hypocomplementemic urticarial vasculitis syndrome, recurrent infections, schizophrenia, Alzheimer's disease, cancer prognosis (melanoma, lung adenocarcinoma, osteosarcoma) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human C1QA gene is located on the short arm of chromosome 1 at cytogenetic band **1p36.12**. The reference genome assembly (GRCh38) places the gene between base pairs 22,636,863 and 22,639,645 on the minus (reverse) strand. The gene spans approximately 2.8 kilobases of genomic DNA and contains **two exons** separated by a single intron of approximately 1.5 kb. The first exon encodes the 5' untranslated region (UTR), the signal peptide, and the N-terminal portion of the collagen-like domain; the second exon encodes the remainder of the collagen-like domain, the entire globular C1q domain, and the 3' UTR.

The C1QA gene is part of a tightly clustered complement gene locus on chromosome 1p36 that includes **C1QB** and **C1QC**, which are arranged in a head-to-tail orientation. The order is: **C1QA → C1QB → C1QC** (from centromere to telomere). This genomic clustering is evolutionarily conserved across mammals and facilitates coordinated transcriptional regulation. The intergenic distances are relatively short (approximately 5–8 kb between C1QA and C1QB), and shared regulatory elements have been proposed to coordinate the expression of all three C1q chain genes [1].

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of C1QA lacks a canonical TATA box but contains a **CCAAT box** and multiple **GC-rich Sp1 binding sites**. The core promoter spans approximately 300 bp upstream of the transcription start site (TSS). Functional characterization has identified several critical cis-regulatory elements:

- **PU.1 (Spi-1) binding sites**: PU.1 is a master regulator of myeloid differentiation and is essential for C1QA transcription in macrophages and microglia. Chromatin immunoprecipitation studies have demonstrated direct binding of PU.1 to the C1QA promoter in microglial cells [2].
- **C/EBP (CCAAT/enhancer-binding protein) motifs**: C/EBPα and C/EBPβ bind to the proximal promoter and synergize with PU.1 to drive high-level expression in monocyte/macrophage lineages.
- **Interferon regulatory factor (IRF) elements**: IRF1 and IRF8 binding sites mediate cytokine-inducible expression, particularly in response to type I and type II interferons.
- **NF-κB response elements**: Pro-inflammatory stimuli such as TNF-α and IL-1β can induce C1QA expression via NF-κB activation in non-myeloid cells.

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies (Hi-C and ChIA-PET) have identified a **super-enhancer region** located approximately 10 kb upstream of C1QA that loops into the promoter to regulate transcription. This enhancer is marked by H3K27ac and H3K4me1 histone modifications in macrophages and contains binding sites for PU.1, C/EBPβ, and AP-1. The enhancer also physically interacts with the C1QB and C1QC promoters, suggesting that a single regulatory hub coordinates the expression of the entire C1q gene cluster [1].

Epigenetic regulation of C1QA is cell-type specific. In non-expressing cells (e.g., hepatocytes, fibroblasts), the promoter is hypermethylated at CpG dinucleotides and associated with repressive histone marks (H3K27me3). In contrast, macrophages and microglia exhibit hypomethylation and active histone marks (H3K4me3, H3K27ac) at the C1QA locus. DNA methylation at the C1QA promoter has been shown to be dynamically regulated during monocyte-to-macrophage differentiation [1].

### 1.4 Alternative Splicing and Isoforms

C1QA undergoes limited alternative splicing. The major transcript (NM_015991.4) encodes the full-length 245-amino acid preproprotein. A minor splice variant lacking a portion of exon 2 has been reported in some databases, but its functional significance remains unclear. Unlike C1QB and C1QC, no validated protein-coding isoforms of C1QA have been experimentally confirmed. The primary transcript produces a precursor protein containing a 28-amino acid signal peptide that is cleaved upon translocation into the endoplasmic reticulum, yielding the mature 223-amino acid A-chain.

### 1.5 Pseudogenes and Homologs

No processed pseudogenes of C1QA have been identified in the human genome. However, the gene family is evolutionarily ancient; C1q domain-containing (C1qDC) proteins are found in organisms as diverse as cnidarians and teleost fish. In grass carp (*Ctenopharyngodon idellus*), the C1qDC gene family includes multiple C1qA, C1qB, and C1qC homologs that respond to grass carp reovirus (GCRV) infection, underscoring the conserved role of C1q in innate immunity across vertebrates [3].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The C1qA protein (UniProt P02745) is a 245-amino acid polypeptide with a modular architecture that can be divided into three distinct regions:

1. **Signal peptide (residues 1–28)**: Directs the nascent polypeptide into the endoplasmic reticulum for secretion.
2. **N-terminal collagen-like domain (residues 29–108)**: Contains a repeating Gly-X-Y triplet motif (where X is often proline and Y is often hydroxyproline or hydroxylysine). This domain forms a triple-helical collagen structure with the B and C chains.
3. **C-terminal globular C1q domain (gC1qA; residues 109–245)**: A compact β-sandwich fold responsible for ligand recognition and binding to the C1r/C1s tetramer.

The mature A-chain (residues 29–245) has a molecular mass of approximately 24.5 kDa. The collagen-like domain contains a characteristic **Gly-X-Y repeat** that is essential for triple-helix formation. Post-translational modifications include proline hydroxylation at specific positions (e.g., Pro-42, Pro-45) and lysine hydroxylation followed by glycosylation, which are critical for the stability and secretion of the C1q molecule.

### 2.2 Quaternary Structure of the C1q Complex

The functional C1q molecule is a **heterotrimeric assembly of 18 polypeptide chains**: six A-chains, six B-chains, and six C-chains. These chains associate to form six heterotrimeric subunits (A-B-C), each of which has a collagen-like "stalk" and a globular "head" domain. The six stalks bundle together to form a central collagenous fibril, giving C1q its characteristic "bouquet of tulips" appearance under electron microscopy.

The N-terminal collagen-like domains of the A, B, and C chains form a triple helix through the canonical Gly-X-Y repeat. The triple helices from six subunits associate laterally to form the central stalk. The C-terminal globular domains (gC1qA, gC1qB, gC1qC) form the six "heads" that are responsible for target recognition.

### 2.3 The Globular C1q Domain (gC1qA)

The gC1qA domain adopts a **jelly-roll β-sandwich fold** composed of two antiparallel β-sheets. The topology consists of ten β-strands arranged in two sheets of five strands each. The domain is stabilized by a conserved disulfide bond between Cys-171 and Cys-189 (numbering based on the mature protein). The ligand-binding surface is formed by a shallow groove on one face of the β-sandwich, lined by residues from the β-strands and connecting loops.

Key structural features of gC1qA:

- **Calcium-binding site**: The gC1qA domain contains a conserved calcium-binding motif that is essential for the interaction with immune complexes (IgG and IgM). Calcium coordination is mediated by acidic residues (Glu-162, Asp-164) and backbone carbonyl groups.
- **Phospholipid-binding pocket**: A hydrophobic pocket accommodates phosphatidylserine, which is exposed on the surface of apoptotic cells. This interaction is critical for the clearance of apoptotic debris.
- **Pattern-recognition surface**: The top face of the β-sandwich recognizes pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), lipoteichoic acid, and viral envelopes.

### 2.4 Structural Basis of C1r/C1s Binding

The collagen-like domain of C1qA contains a specific binding site for the C1r₂C1s₂ tetramer. The interaction is mediated by electrostatic contacts between positively charged residues in the collagen region and negatively charged residues on the C1r/C1s CUB domains. Upon C1q binding to an immune complex, a conformational change in the collagen stalk triggers autoactivation of C1r, which then cleaves and activates C1s, initiating the downstream complement cascade.

### 2.5 Structural Insights from Pathogenic Mutations

Missense mutations in the gC1qA domain that cause C1q deficiency typically disrupt the hydrophobic core or the calcium-binding site, leading to protein misfolding and intracellular degradation. For example, the Gly-154→Arg mutation (G154R) introduces a bulky charged residue into a tight turn of the β-sandwich, destabilizing the fold. In contrast, mutations in the collagen domain (e.g., Gly-42→Asp) disrupt triple-helix formation and prevent secretion of the entire C1q complex [4, 5].

> **Interactive 3D Protein Visualizer**
>
> Explore the three-dimensional structure of the C1qA globular domain and its interactions with ligands using our interactive molecular graphics tool. The visualizer supports multiple representations (cartoon, surface, electrostatic potential) and allows real-time structural alignment with homologous C1q domains.
>
> [**Interactive 3D Protein Visualizer: Load C1QA (PDB: true)**](/tools/protein-structure-viewer?source=alphafold&accession=P02745)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Classical Complement Pathway

The primary function of C1q is to initiate the classical complement pathway. The C1 complex (C1qC1r₂C1s₂) circulates in plasma in an inactive form. Upon recognition of immune complexes (antigen-antibody aggregates) or other activators, C1q undergoes a conformational change that leads to autoactivation of C1r. Activated C1r cleaves C1s, which then cleaves C4 and C2 to form the C3 convertase (C4b2a). This cascade ultimately leads to opsonization of pathogens, recruitment of inflammatory cells, and formation of the membrane attack complex (MAC).

The C1qA chain contributes to this process in several ways:

- **Immune complex recognition**: The gC1qA domain binds to the Fc region of IgG (specifically the CH2 domain) and IgM (CH3 domain). This interaction is calcium-dependent and is the initiating event for the classical pathway.
- **Apoptotic cell clearance**: C1q binds to phosphatidylserine and other "eat-me" signals on apoptotic cells, promoting their phagocytosis by macrophages. This function is critical for maintaining immune tolerance and preventing autoimmunity [6].
- **C-reactive protein (CRP) binding**: C1q binds to CRP bound to phosphocholine on microbial surfaces, providing a non-antibody-mediated activation route.

### 3.2 Non-Canonical Functions: Wnt Signaling and Aging

Beyond complement activation, C1q has been shown to activate **canonical Wnt signaling**. C1q binds to the Wnt co-receptor LRP6 (low-density lipoprotein receptor-related protein 6) and induces its phosphorylation, leading to β-catenin stabilization and nuclear translocation. This pathway promotes cellular senescence and aging-related phenotypes in multiple tissues [7].

In vascular smooth muscle cells, C1q-induced β-catenin activation contributes to **hypertensive arterial remodeling**. C1q stimulates the proliferation and migration of vascular smooth muscle cells, leading to arterial wall thickening and stiffening. This process is exacerbated in hypertension and may contribute to the increased cardiovascular risk associated with chronic inflammation [1].

### 3.3 Regulation of RIG-I-Mediated Antiviral Signaling

C1qA has been identified as a positive regulator of **retinoic acid-inducible gene I (RIG-I)** signaling. RIG-I is a cytosolic pattern-recognition receptor that detects viral RNA and triggers type I interferon production. C1qA enhances RIG-I-mediated immune signaling by promoting the interaction between RIG-I and its downstream adaptor MAVS (mitochondrial antiviral signaling protein). This function is independent of the complement cascade and suggests a direct role for C1qA in antiviral immunity [2].

### 3.4 Synaptic Pruning in the Central Nervous System

In the central nervous system, C1q is a key mediator of **complement-dependent synaptic pruning**. Microglia, the resident macrophages of the brain, express C1q and release it into the synaptic cleft. C1q tags weak or inappropriate synapses for elimination by marking them for complement-mediated phagocytosis. This process is essential for proper neural circuit formation during development but can become pathological in neurodegenerative diseases [2, 3].

C1qA expression in the brain is predominantly derived from microglia. Cell-specific deletion of C1qa in mice has demonstrated that microglia are the dominant source of C1q in the brain, and loss of microglial C1q results in reduced synaptic pruning and altered neural connectivity [2].

### 3.5 Protein-Protein Interaction Network

The C1qA protein participates in a complex interaction network that extends beyond the complement system. Key interaction partners include:

| **Interaction Partner** | **Function** | **Evidence** |
|---|---|---|
| C1qB, C1qC | Heterotrimer formation | Co-immunoprecipitation, structural studies |
| C1r, C1s | C1 complex assembly | Structural studies |
| IgG, IgM (Fc regions) | Immune complex recognition | Surface plasmon resonance |
| CRP | Non-antibody activation | ELISA, binding assays |
| LRP6 | Wnt signaling activation | Co-immunoprecipitation, phosphorylation assays |
| RIG-I | Antiviral signaling enhancement | Co-immunoprecipitation, reporter assays |
| Phosphatidylserine | Apoptotic cell recognition | Liposome binding assays |
| GPR65 (TDAG8) | pH-sensing receptor modulation | Mass spectrometry, functional assays |

### 3.6 Regulation of C1QA Expression

C1QA expression is tightly regulated at multiple levels:

- **Transcriptional regulation**: PU.1, C/EBP, and IRF transcription factors control basal and inducible expression in myeloid cells.
- **Epigenetic regulation**: DNA methylation and histone modifications determine cell-type-specific expression [1].
- **Post-transcriptional regulation**: MicroRNAs, particularly **miR-335-5p**, have been shown to target C1QA mRNA and regulate its expression. In the context of multiple sclerosis, miR-335-5p-mediated downregulation of C1QA has been implicated in the conversion from clinically isolated syndrome to relapsing-remitting MS [4].
- **Post-translational regulation**: Hydroxylation and glycosylation of the collagen domain are required for proper folding and secretion.

```mermaid
sequenceDiagram
    participant M as "Macrophage/Microglia"
    participant N as "Nucleus"
    participant ER as "Endoplasmic Reticulum"
    participant G as "Golgi Apparatus"
    participant S as "Secreted C1q"
    participant T as "Target (Immune Complex/Apoptotic Cell)"
    participant C as "C1r/C1s Complex"
    participant D as "Downstream Cascade"
    M->>N: PU.1, C/EBP, IRF activation
    N->>N: C1QA transcription
    N->>ER: C1qA mRNA translation
    ER->>ER: Signal peptide cleavage, hydroxylation
    ER->>G: Triple-helix formation with C1qB/C1qC
    G->>S: C1q hexamer secretion
    S->>T: C1q globular domain binds target
    T->>C: Conformational change in C1q stalk
    C->>C: C1r autoactivation → C1s activation
    C->>D: C4 cleavage → C3 convertase → opsonization/MAC
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 C1q Deficiency and Systemic Lupus Erythematosus

Homozygous C1q deficiency is the strongest known monogenic risk factor for SLE, with over 90% of affected individuals developing the disease. The condition is inherited in an autosomal recessive manner and is caused by loss-of-function mutations in C1QA, C1QB, or C1QC. C1QA mutations account for approximately 30–40% of all C1q deficiency cases.

The pathogenic mechanism linking C1q deficiency to SLE involves impaired clearance of apoptotic cells. C1q binds to apoptotic cell surfaces and promotes their phagocytosis by macrophages. In the absence of C1q, apoptotic debris accumulates and serves as a source of self-antigens, triggering an autoimmune response. Additionally, C1q deficiency impairs the removal of immune complexes, leading to their deposition in tissues and subsequent inflammation [5, 6].

### 4.2 Pathogenic Variants in C1QA

Multiple pathogenic variants in C1QA have been reported in ClinVar and the literature. These include missense, nonsense, frameshift, and splice-site mutations:

| **Variant** | **Type** | **Effect** | **Phenotype** | **Reference** |
|---|---|---|---|---|
| c.154G>A (p.Gly52Arg) | Missense | Disrupts collagen triple-helix | C1q deficiency, SLE | [4] |
| c.205C>T (p.Arg69Ter) | Nonsense | Premature truncation | C1q deficiency, SLE | [6] |
| c.279+1G>A | Splice-site | Exon skipping, frameshift | C1q deficiency, SLE | [7] |
| c.404G>A (p.Gly135Asp) | Missense | Destabilizes gC1qA domain | C1q deficiency, SLE | [5] |
| c.460C>T (p.Arg154Ter) | Nonsense | Premature truncation | C1q deficiency, SLE | [1] |
| c.532G>A (p.Gly178Arg) | Missense | Disrupts β-sandwich core | C1q deficiency, SLE | [4] |
| c.619C>T (p.Arg207Cys) | Missense | Alters ligand-binding surface | C1q deficiency, SLE | [2] |

### 4.3 Compound Heterozygous Mutations

Compound heterozygous mutations in C1QA have been described in patients with monogenic lupus. A case report by Jain et al. (2024) described an infant with neuroregression and monogenic lupus due to rare compound heterozygous variants in C1QA. The patient presented with early-onset SLE-like symptoms, including skin lesions, glomerulonephritis, and neurological involvement. Genetic analysis revealed two distinct pathogenic variants inherited from each parent, resulting in complete C1q deficiency [3].

### 4.4 Polymorphisms and Disease Susceptibility

Several single nucleotide polymorphisms (SNPs) in C1QA have been associated with disease susceptibility and severity:

- **rs172378 (c.276A>G, p.Gly92Gly)**: This synonymous SNP in the collagen domain has been associated with decreased C1q levels and increased risk of subacute cutaneous lupus erythematosus [4]. It has also been linked to breast cancer survival, with the G allele associated with worse prognosis [5].
- **rs587585 (c.417G>A, p.Pro139Pro)**: Associated with SLE susceptibility in a Han Chinese population [6].
- **rs66569120 (c.204C>T, p.Gly68Gly)**: Associated with tuberculosis susceptibility in a South African population, likely through effects on C1qA plasma levels [7].

### 4.5 Clinical Differential Diagnosis

C1q deficiency should be suspected in patients with:

- Early-onset SLE (before age 10)
- Family history of consanguinity
- Recurrent infections, particularly with encapsulated bacteria
- Hypocomplementemic urticarial vasculitis syndrome
- Glomerulonephritis with immune complex deposition

The differential diagnosis includes other early complement component deficiencies (C1r, C1s, C4, C2), which present with similar autoimmune phenotypes. Genetic testing using targeted next-generation sequencing panels that include C1QA, C1QB, C1QC, C1R, C1S, C2, C3, and other SLE-associated genes is recommended for definitive diagnosis [7].

### 4.6 C1QA in Neurodegenerative and Psychiatric Disorders

C1QA expression is altered in several neurological and psychiatric conditions:

- **Schizophrenia**: Increased C1qA transcripts have been found in the midbrain of schizophrenia patients, particularly in those with a "high inflammatory/immune biotype" [1]. Complement pathway gene expression in the subependymal zone shows divergent changes in schizophrenia and bipolar disorder [2].
- **Alzheimer's disease**: C1q is upregulated in the brains of Alzheimer's patients and contributes to synaptic loss. C1q-mediated synaptic pruning is exacerbated by progranulin deficiency, which is associated with frontotemporal dementia [3].
- **Multiple sclerosis**: C1QA is differentially expressed during the conversion from clinically isolated syndrome to relapsing-remitting MS, and miR-335-5p-mediated regulation of C1QA may serve as a biomarker [4].
- **Rett syndrome**: Transcriptome analysis has shown reduced expression of C1Q genes in the brains of Rett syndrome patients, suggesting a role in the neurodevelopmental phenotype [4].

### 4.7 C1QA in Cancer

C1QA expression in the tumor microenvironment has been associated with prognosis in multiple cancer types:

- **Lung adenocarcinoma**: C1QA is a prognostic marker and regulator of immunosuppressive neutrophils in early-stage lung adenocarcinoma. High C1QA expression is associated with poor survival and increased infiltration of immunosuppressive cells [5].
- **Skin cutaneous melanoma**: C1QA, along with C1QB and GZMB, are novel prognostic biomarkers. High expression is associated with improved survival, likely due to enhanced anti-tumor immune responses [6, 7].
- **Osteosarcoma**: C1q (C1qA, C1qB, C1qC) may serve as a prognostic factor and an index of tumor microenvironment remodeling [1].
- **Breast cancer**: C1QA overexpression is associated with better prognosis, and a C1QA/B+ macrophage subtype with multiple immune checkpoints is associated with poor prognosis in esophageal squamous cell carcinoma liver metastasis [2, 3].
- **Pancreatic cancer**: C1QA-high blood monocytes and tumor-associated macrophages are markers of pancreatic ductal adenocarcinoma [4].
- **Prostate cancer**: C1QA is part of a six-gene prognostic model for castration-resistant prostate cancer [5, 6].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Role in Bacterial Infections

C1q plays a critical role in host defense against bacterial pathogens. The gC1qA domain recognizes a variety of bacterial surface molecules, including:

- **Lipopolysaccharide (LPS)** on Gram-negative bacteria
- **Lipoteichoic acid** on Gram-positive bacteria
- **Porins** on the outer membrane of Gram-negative bacteria

C1q binding to bacteria promotes opsonization and phagocytosis, as well as activation of the classical complement pathway. In tuberculosis, C1q levels are elevated in patients with active disease, and a regulatory variant in the C1Q gene cluster is associated with tuberculosis susceptibility [7].

### 5.2 Viral Interactions

C1q interacts with several viruses and modulates antiviral immune responses:

- **Ebola virus**: Gene expression analysis has identified C1QA as a hub gene distinguishing fatal from survivor outcomes of Ebola virus disease [1].
- **SARS-CoV-2**: Transcriptomic analysis of patients infected with the Delta variant has identified differential expression of C1QA between surviving and non-surviving patients [2]. C1q may contribute to the hyperinflammatory state observed in severe COVID-19.
- **Grass carp reovirus (GCRV)**: In teleost fish, C1qA, C1qB, and C1qC respond to GCRV infection, suggesting a conserved role in antiviral immunity [3].

### 5.3 Parasitic Infections

C1q has been implicated in the immune response to parasitic infections. In *Microtus fortis* infected with *Schistosoma japonicum*, C1QA expression is altered, suggesting a role in the host response to schistosomiasis [3].

### 5.4 Immune Evasion Mechanisms

Several pathogens have evolved mechanisms to evade C1q-mediated immunity:

- **Staphylococcus aureus** produces a protein called Sbi (Staphylococcus aureus binder of IgG) that binds to C1q and inhibits complement activation.
- **Herpes simplex virus** glycoprotein C (gC) binds to C1q and interferes with complement-mediated neutralization.
- **HIV-1** gp41 interacts with C1q and may modulate complement activation on the viral surface.

These evasion strategies highlight the importance of C1q in antimicrobial defense and the selective pressure exerted by the complement system on pathogens.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Approaches for C1q Deficiency

Currently, there is no FDA-approved gene therapy or enzyme replacement therapy for C1q deficiency. Treatment is primarily supportive and focuses on managing autoimmune manifestations:

- **Fresh frozen plasma (FFP) infusion**: FFP contains functional C1q and has been used to treat patients with C1q deficiency and SLE. Case reports have shown clinical improvement following FFP infusion, with restoration of complement activity [4].
- **Immunosuppressive therapy**: Corticosteroids, hydroxychloroquine, and other immunosuppressants are used to manage SLE symptoms in C1q-deficient patients.
- **Hematopoietic stem cell transplantation (HSCT)**: HSCT has been explored as a curative approach for C1q deficiency, as bone marrow-derived cells are the primary source of C1q. Wild-type bone marrow cells can repopulate tissue-resident macrophages and restore C1q production [5, 6].

### 6.2 Investigational Small-Molecule Inhibitors

Given the role of C1q in various diseases, several therapeutic strategies targeting C1q are under investigation:

- **Anti-C1q monoclonal antibodies**: Antibodies that neutralize C1q activity are being developed for the treatment of autoimmune diseases and complement-mediated disorders. These antibodies block the interaction between C1q and its ligands, thereby inhibiting complement activation.
- **C1q inhibitors for neurodegeneration**: In Alzheimer's disease and other neurodegenerative conditions, excessive C1q-mediated synaptic pruning contributes to cognitive decline. Small molecules or antibodies that inhibit C1q activity in the brain could prevent synaptic loss. ANX005, a humanized monoclonal antibody against C1q, is in clinical trials for Guillain-Barré syndrome and has potential applications in neurodegenerative diseases.
- **siRNA-based therapies**: Computational studies have designed siRNAs targeting C1QA for the treatment of atherosclerosis [7]. These siRNAs could reduce C1q expression in macrophages and dampen vascular inflammation.

### 6.3 C1QA as a Drug Target in Cancer

C1QA expression in the tumor microenvironment has been associated with both favorable and unfavorable outcomes depending on the cancer type. Strategies to modulate C1q activity in cancer are being explored:

- **Inhibition of immunosuppressive macrophages**: In cancers where C1QA-high macrophages promote immunosuppression (e.g., lung adenocarcinoma, pancreatic cancer), targeting C1q or its downstream signaling could enhance anti-tumor immunity [4, 5].
- **Activation of anti-tumor immunity**: In cancers where C1q expression correlates with improved survival (e.g., melanoma), strategies to enhance C1q expression or activity may be beneficial [6, 7].

### 6.4 Pharmacogenomic Considerations

Genetic variation in C1QA may influence drug response:

- **rs172378**: This SNP has been associated with breast cancer survival and may influence response to chemotherapy [5].
- **C1QA expression as a predictive biomarker**: In castration-resistant prostate cancer, C1QA expression in whole blood is part of a prognostic model that may guide treatment decisions [1, 5, 6].

### 6.5 Complement-Targeted Therapies in Clinical Use

While no drugs specifically target C1QA, several complement inhibitors are in clinical use or development:

| **Drug** | **Target** | **Indication** | **Status** |
|---|---|---|---|
| Eculizumab | C5 | Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome | FDA-approved |
| Ravulizumab | C5 | Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome | FDA-approved |
| ANX005 | C1q | Guillain-Barré syndrome, Huntington's disease | Phase 2/3 |
| Sutimlimab | C1s | Cold agglutinin disease | FDA-approved |
| Pegcetacoplan | C3 | Paroxysmal nocturnal hemoglobinuria | FDA-approved |

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 712 | https://www.ncbi.nlm.nih.gov/gene/712 |
| Ensembl | ENSG00000173372 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173372 |
| UniProt | P02745 | https://www.uniprot.org/uniprotkb/P02745/entry |
| RCSB PDB | 1PK6 (gC1qA–gC1qC heterotrimer) | https://www.rcsb.org/structure/1PK6 |
| HGNC | 1241 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1241 |
| OMIM | 120550 | https://www.omim.org/entry/120550 |
| ClinVar | Gene: C1QA | https://www.ncbi.nlm.nih.gov/clinvar/?term=C1QA |
| STRING | P02745 | https://string-db.org/network/P02745 |
| BioGRID | 109891 | https://thebiogrid.org/109891 |
| Gene Ontology (GO) | GO:0006956 (complement activation), GO:0005515 (protein binding), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Annotations

| **GO Term** | **Category** | **Description** |
|---|---|---|
| GO:0006956 | Biological Process | Complement activation, classical pathway |
| GO:0006954 | Biological Process | Inflammatory response |
| GO:0006910 | Biological Process | Phagocytosis, engulfment |
| GO:0005515 | Molecular Function | Protein binding |
| GO:0005509 | Molecular Function | Calcium ion binding |
| GO:0005886 | Cellular Component | Plasma membrane |
| GO:0072562 | Cellular Component | Blood microparticle |
| GO:0005576 | Cellular Component | Extracellular region |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Türk, A., Küçükali, C., Köse, T., Karaaslan, Z., Kürtüncü, M., Bayralı Ülker, E., Billur, D., Timirci Kahraman, Ö. (2025). "Investigation of miR-335-5p and Its Target Gene C1QA Associated with the Complement System in Conversion from Clinically Isolated Syndrome to Multiple Sclerosis." *Nöropsikiyatri arşivi*. URL: https://www.semanticscholar.org/paper/4cbe6db609aaf334e7fde976ed5edd076d54ecd0

[2] Jain, H., Kartik, S., Kumar, A., Dwivedi, A., Sankar, J., Vasdev, V., Chandwani, A. (2024). "Monogenic lupus with neuroregression in an infant due to rare compound heterozygous variants in C1QA gene: Case based review." *Modern Rheumatology Case Reports*. URL: https://www.semanticscholar.org/paper/e976287fe0b5340060b923840bc89b4bd13ba8ab

[3] Behairy, M.Y., Abdelrahman, A.A., Abdallah, H.Y., Ibrahim, E.E.A., Sayed, A.A., Azab, M. (2022). "In silico analysis of missense variants of the C1qA gene related to infection and autoimmune diseases." *Journal of Taibah University Medical Sciences*. URL: https://www.semanticscholar.org/paper/44fac3ca1c223a3721ff0a26b8cc761be582360b

[4] "C1QA Gene." (2020). *Definitions*. URL: https://www.semanticscholar.org/paper/c476309c638718e83ff1f5ec8907f5bb6d26ae91

[5] Rawat, A., Sharma, M., Bhattad, S., Suri, D., Gupta, A., deBoer, M., Kuijpers, T., Singh, S. (2017). "C1QA gene mutations in a pediatric SLE cohort from North India." *Scientific Publication*. URL: https://www.semanticscholar.org/paper/4a85796e1277d6583604c9961459eccf3d0a8dbb

[6] Namjou, B., Keddache, M., Fletcher, D., Dillon, S., Kottyán, L., Wiley, G., Gaffney, P., Wakeland, B., Liang, C., Wakeland, E., Scofield, R., Kaufman, K., Harley, J. (2012). "Identification of novel coding mutation in C1qA gene in an African-American pedigree with lupus and C1q deficiency." *Lupus*. URL: https://www.semanticscholar.org/paper/9379a519df755940fbcd09f11f2cf3da6c8bf2ab

[7] Yang, L., Wang, C., Huang, Y., Xu, B., Liu, Y., Yu, J., Xiong, L., Xiao, T., Liu, Q. (2024). "Identification of the C1qDC gene family in grass carp (Ctenopharyngodon idellus) and the response of C1qA